The feasibility of uPA/uPAR-targeting strategies in cancer treatment

Cancer Biology and Therapy

Volumn 7, Issue 5, 2008, Pages 660-662

  Sheng, Shijie ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; FORMYLMETHIONYLLEUCYLPHENYLALANINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; INTEGRIN; PLASMINOGEN; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN; CELL SURFACE RECEPTOR; UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTORS;

BIOLOGICAL ACTIVITY; CANCER THERAPY; CELL ADHESION; CELL GROWTH; CELL INTERACTION; CELL SURVIVAL; CHEMOTAXIS; DOWN REGULATION; DRUG TARGETING; EXTRACELLULAR MATRIX; FEASIBILITY STUDY; NOTE; PROTEIN DEGRADATION; PROTEIN INTERACTION; ANIMAL; BIOLOGICAL MODEL; CATALYSIS; CELL PROLIFERATION; CHEMISTRY; HUMAN; METASTASIS; NEOPLASM; PHENOTYPE;

ANIMALS; CATALYSIS; CELL PROLIFERATION; EXTRACELLULAR MATRIX; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; PHENOTYPE; RECEPTORS, CELL SURFACE; URINARY PLASMINOGEN ACTIVATOR;

EID: 56149115949     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.5.6076     Document Type: Note

References (33)

1. Bugge TH, Suh TT, Flick MJ, et al. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem 1995; 270:16886-94.
2. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008; 34:122-36.
3. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3:932-43.
4. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003; 3:489-501.
5. Shi Z, Stack MS. Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity. Biochem J 2007; 407:153-9.
6. Robison AK CD. Activation of the fibrinolytic system. Cardiol Clin 1987; 5:13-9.
7. Gurewich V. Fibrinolysis: an unfinished agenda. Blood Coagul Fibrinolysis 2000; 11:401-8.
8. Rijken D. Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Baillieres Clin Haematol 1995; 8:291-312.
9. Rickli E. The activation mechanism of human plasminogen. Thromb Diath Haemorrh 1975; 34:386-95.
10. Rabbani SA MA. The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am 2001; 10:393-415.
11. Pepper M. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21:1104-17.
12. Legrand C PM, Tournier JM, de Bentzmann S, Huet E, Monteau M, Birembaut P. uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration. Exp Cell Res 2001; 264:326-36.
13. Naldini LTL, Vigna E, Sachs M, Hartmann G, Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio PM. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 1992; 11:4825-33.
14. Miyazawa KWY, Minoshima S, Shimizu N, Kitamura N. Structural organization and chromosomal localization of the human hepatocyte growth factor activator gene - phylogenetic and functional relationship with blood coagulation factor XII, urokinase, and tissue-type plasminogen activator. Eur J Biochem 1998; 258:355-61.
15. Ustach CV, Kim HR. Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol 2005; 25:6279-88.
16. Yee JA, Yan L, Dominguez JC, Allan EH, Martin TJ. Plasminogen-dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblast-like cells. J Cell Physiol 1993; 157:528-34.
17. Zhang L SD, Cines DB, Higazi AA. Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide. J Biol Chem 1997; 272:27053-7.
18. Nykjaer A, Conese M, Christensen EI, et al. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 1997; 16:2610-20.
19. Nykjaer A, Petersen CM, Moller B, et al. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 1992; 267:14543-6.
20. Kounnas MZ, Henkin J, Argraves WS, Strickland DK. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates cellular uptake of pro-urokinase. J Biol Chem 1993; 268:21862-7.
21. Yin S, Lockett J, Meng Y, et al. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. Cancer Res 2006; 66:4173-81.
22. Furlan F, Orlando S, Laudanna C, et al. The soluble D2D3(88-274) fragment of the urokinase receptor inhibits monocyte chemotaxis and integrin-dependent cell adhesion. J Cell Sci 2004; 117:2909-16.
23. Steinmetzer T. Synthetic urokinase inhibitors as potential antitumor drugs. IDrugs 2003; 6:138-46.
24. Liu S, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 2001; 276:17976-84.
25. Zhu F, Jia S, Xing G, Gao L, Zhang L, He F. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis. DNA Cell Biol 2001; 20:297-305.
26. Luparello C, Del Rosso M. In vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells. Eur J Cancer 1996; 32:702-7.
27. Colomer R, Shamon LA, Tsai MS, Lupu R. Herceptin: from the bench to the clinic. Cancer Invest 2001; 19:49-56.
28. Starling N, Cunningham D. Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions. Curr Opin Oncol 2004; 16:385-90.
29. Todhunter DA, Hall WA, Rustamzadeh E, Shu Y, Doumbia SO, Vallera DA. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel 2004; 17:157-64.
30. Rustamzadeh E, Li C, Doumbia S, Hall WA, Vallera DA. Targeting the overexpressed urokinase-type plasminogen activator receptor on glioblastoma multiforme. J Neurooncol 2003; 65:63-75.
31. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res 2007; 13:4051-60.
32. Pulukuri SM, Gondi CS, Lakka SS, et al. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005; 280:36529-40.
33. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 2004; 23:8486-96.